Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 2, 1996, Pages 449-459

  Eissenberg, Thomas ^a   Greenwald, Mark K ^a,b   Johnson, Rolley E ^a   Liebson, Ira A ^a   Bigelow, George E ^a   Stitzer, Maxine L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NALOXONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; DOSE RESPONSE; FEMALE; HUMAN; MALE; MIDDLE AGED; OPIATE ADDICTION; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0030087729     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. AZORLOSA, J. L., STITZER, M. L AND GREENWALD, M. K.: Opioid physical dependence development: Effects of single versus repeated morphine pretreatments and of subjects' opioid exposure history. Psychopharmacology 114: 71-80, 1994.
2. BICKEL, W. K., STITZEB, M. L., LIEBSOK, I. A. AND BIGEILOW, G E., Acute physical dependence in man: Effects of naloxone after brief morphine exposure. J. Pharmacol. Exp. Ther. 244: 126-132, 1988.
3. BLASIG, J., HOLLT, V , HERZ, A. AND PASCHELKE, G.: Comparison of withdrawal precipitating properties of various morphine antagonists and partial agonists in relation to their stereospecific binding to brain homogenates. Psychopharmacologia 46: 41-51, 1976.
4. CHESKIN, L. J., FUDALA, P. J. AND JOHNSON, R. E.: A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend. 36: 116-121, 1994.
5. CHIANG, C. N., BRIDGE, P., HAWKS, R., HERBERT, S., HILL, J., MAGHRABLIAN, L., SEGAL, D., TEERILL, J. ANB WALSH, R.: The development of buprenorphinenaloxone products for treating opiate dependence. Abstract Presented at the Fifty-Seventh Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc., June 10-15, Scottsdale, 1995
6. COWAN, A., LEWIS, J. W. AND MCFARLANE, I. R: Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60: 537-545, 1977.
7. DUM, J., BLASIG, J. AND HERZ, A.: Buprenorphine: Demonstration of physical dependence liability. Eur. J. Pharmacol. 70: 293-300, 1981.
8. FINNEY, D J : Statistical Method in Biological Assay, Hafner Publishing, New York, 1964.
9. FUDALA, P. J., JAFFE, J. H., DAX, E. M. AND JOHNSON, R. E.: Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin. Pharmacol. Ther. 47: 525-534, 1990.
10. FUDALA, P. J., LANGE, R. W., COLLINS, C. C. AND JOHNSON, R. E.: Effects of agonist and antagonist challenges in buprenorphine treated volunteers. Abstract from the 96th Annual Convention of the American Psychological Association, Division 28, Aug. 12-15, Atlanta, 1988.
11. GAL, T. J.: Naloxone reversal of buprenorphine-induced respiratory depression. Clin. Pharmacol. Ther. 45: 66-71, 1989
12. GREENWALD, M K., SCHUSTER, C. R. AND JOHANSON, C.-E.: Drug craving during naloxone-precipitated withdrawal in methadone maintained volunteers. Abstract Presented at the Fifty-Seventh Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc., June 10-15, Scottsdale, 1995.
13. HAERTZEN, C A.: An Overview of Addiction Research Center Inventory Scales (ARCI): An Appendix and Manual of Scales, DHEW Publication No. (ADM) 74-92, National Institute on Drug Abuse, Rockville, 1974.
14. HAMBROOK, J. M. AND RANCE, M. J.: The interaction of buprenorphine with the opiate receptor: Lipophilicity as a determining factor in drug-receptor kinetics. In Opiates and Endogenous Opioid Peptides, ed. by H. W. Kosterlitz, pp. 295-301, Elsevier, 1976.
15. HEISHMAN, S. J., STITZER, M. L., BIGELOW, G. E. AND LIEBSON, I. A.: Acute opioid physical dependence in postaddict humans: Naloxone dose effects after brief morphine exposure. J. Pharmacol. Exp. Ther. 248: 127-134, 1989
16. HIMMELSBACH, C. K.: The morphine abstinence syndrome, its nature and treatment. Annu. Int. Med. 15: 829-839, 1941.
17. JASINSKI, D. R , PEVNICK, J. S. AND GRIFFITH, J. D.: Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry 35: 501-516, 1978.
18. JOHNSON, R. E., EISSINBERG, T., ALIM, T. N., LINDQUIST, T., VOCCI, F. J., RISHER-FLOWERS, D. L. AND DEUTSCH, S. I.: Comparison of the withdrawal syndromes following abrupt termination of buprenorphine and methadone. Abstract Presented at the Fifty-Seventh Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc., June 10-15, Scottsdale, 1995a
19. JOHNSON, R. E., EISSENBERG, T., STITZER, M. L., STRAIN, E. C., LIEESON, I. A. AND BIGELOW, G. E.: A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend., in press, 1995b
20. JOHNSON, R. E., FUDALA, P. J. AND JAFFE, J. H.: A controlled trial of buprenorphine for opioid dependence. J. Am. Med. Assoc. 267: 2750-2755, 1992.
21. KOSTEN, T. R., KRYSTAL, J. H., CHARNEY, D. S., PRICE, L. H., MORGAN, C. H AND KLEBER, H. D : Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend 25: 73-78, 1990.
22. MARTIN, W. R., EADES, C. G., THOMPSON, J. A., HUPPLER, R. E. AND GILBERT, P. E.: The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197:517-532, 1976.
23. MARTIN, W. R., JASINSKI, D. R. AND MANSKY, P. A.: Naltrexone, an antagonist for the treatment of heroin dependence. Arch. Gen. Psychiatry 28: 784-791, 1973.
24. MARTIN, W. R., SLOAN, J. W., SAPIRA, J. D. AND JASINSKI, D. R.: Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin. Pharmacol. Ther. 12: 245-258, 1971.
25. MEDICAL ECONOMICS DATA: Physician's Desk Reference, Medical Economics Data Production Company, Montvale, 1995.
26. MELLO, N. K. AND MENDELSON, J. H.: Buprenorphine suppresses heroin use by heroin addicts. Science (Wash. DC) 207: 657-659, 1980.
27. NIGAM, A. K., SRIVASTAVA, R. P., SAXENA, S., CHAVAN, B. S. AND SUNDARAM, K. R.: Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction 89: 317-320, 1994.
28. PRESTON, K. L., BIGELOW, G. E. AND LIEBSON, I A.: Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J. Pharmacol. Exp. Ther. 246: 441-448, 1988.
29. ROTHMAN, R. B., Ni, Q. AND Xu, H.: Buprenorphine: A review of the binding literature. In Buprenorphine: Combatting Drug Abuse with a Unique Opioid, ed. by A. Cowan and J. W. Lewis, pp. 19-29, Wiley-Liss, Inc. New York, 1995
30. SCHUH, K., WALSH, S. L., STITZEK, M. L., PRESTON, K. L. AND BIGELOW, G. E.: Effects of buprenorphine in morphine-dependent subjects. In Problems of Drug Dependence, 1993: Proceedings of the 55th Annual Scientific Meeting, the College on Problems of Drug Dependence, Inc., Volume II, ed. by L. S. Harris, p. 383, NIDA Research Monograph 141 (NIDA Publication No. 94-3749), National Institutes of Health, Rockville, 1993.
31. SHANNON, H E. AND HOLTZMAN, S. G.: Blockade of the discriminative effects of morphine in the rat by naltrexone and naloxone. Psychopharmacology 50: 119-124, 1976.
32. SPITZER, R. L. AND WILLIAMS, J. B. W.: Structured Interview for DSM-III-R (SCID), New York State Psychiatric Institute, Biometrics Research, New York, 1987.
33. STRAIN, E. C , PRESTON, K. L., LIEBSON, I. A AND BIGELOW, G. E.: Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J. Pharmacol. Exp. Ther. 261: 985-993, 1992.
34. STRAIN, E. C., PRESTON, K. L., LIEBSON, I. A. AND BIGELOW, G. E.: Buprenorphine effects in methadone-maintained volunteers: Effects at two hours after methadone. J. Pharmacol. Exp. Ther. 272: 628-638, 1995.
35. SWAIN, H. H. AND SEEVERS, M. H.: Evaluation of new compounds for morphine-like physical dependence in the rhesus monkey. In Proceedings of the Committee on Problems of Drug Dependence, 37th Meeting, Addendum, pp. 773-795, National Academy of Sciences, Washington DC, 1975.
36. TAKEMORI, A. E. AND POETOGHESE, P. S.: Comparative antagonism by naltrexone and naloxone of μ, κ, and δ agonists. Eur. J. Pharmacol. 104: 101-104, 1984.
37. TEAL, J. J. AND HOLTZMAN, S. G.: Stimulus effects of morphine in the monkey: Quantitative analysis of antagonism. Pharmacol. Biochem. Behav. 12: 587-593, 1980.
38. VAN DYCK, C. H., ROSEN, M. I., THOMAS, H. M., MCMAHON, T. J., WALLACE, E. A., O'CONNOR, P G., SULLIVAN, M., KRYSTAL, J. H., HOFFER, P. B., WOODS, S. W. AND KOSTEN, T. R.: SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine. Psychiatry Res. Neuroimaging 55: 181-191, 1994.
39. WALSH, S. L., PRESTON, K. L., BIGELOW, G. E. AND STITZER, M. L.: Acute administration of buprenorphine in humans: Partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274: 361-372, 1995.
40. WALSH, S. L., PRESTON, K. L., STITZER, M. L., CONE, E. J. AND BIGELOW, G. E.: Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin. Pharmacol. Ther. 55; 569-580, 1994.
41. WEINHOLD, L. L., PRESTON, K. L., FARRE, M., LIEBSON, I. A. AND BIOELOW, G. E.: Buprenorphine alone and in combination with naloxone in nondependent humans. Drug Alcohol Depend. 30: 263-274, 1992.
42. WIKLER, A., FRASER, H. AND ISBELL, H: N-allyllnormorphine: Effects of single doses and precipitation of acute "abstinence syndromes" during addiction to morphine, methadone, or heroin in man (post-addicts). J. Pharmacol. Exp. Ther. 109: 8-20, 1953.